Purpose: Because dry eye greatly reduces quality of life, this study aimed to examine rebamipide instillation in patients with dry eye and assess the improvement of signs and symptoms as evaluated with the Ocular Surface Disease Index, which is the most popular index and is highly reliable.
Introduction
According to Japanese diagnostic criteria 1 , dry eye is defined as a chronic multifactorial disease of the tears and keratoconjunctival epithelium and is accompanied by ocular discomfort and visual dysfunction. The mainstream treatment for dry eye is eye drops. The first-line treatment in the United States is cyclosporine instillation, whereas the drugs of first choice in Japan are hyaluronate ophthalmic solutions. Now marketed in Japan, however, are diquafosol ophthalmic solution (Diquas Ophthalmic Solution 3%; Santen Pharmaceutical Co., Ltd., Osaka, Japan) and rebamipide ophthalmic solution (Mucosta ophthalmic suspension UD2%; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). Both ophthalmic solutions induce mucin production 2, 3 .
Of the 2 agents, rebamipide has a long history of use and was originally launched in 1990 as an oral medication for repairing the gastric mucosa by stimulating mucin production 4, 5 . Rebamipide also exerts further effects on the ocular surface cells. Experiments have shown that rebamipide increases the amount of mucinlike substances in the conjunctival goblet cells and in keratoconjunctival epithelial cells in vitro and in vivo 2, 6, 7 . In addition, as a clinical topical agent rebamipide has been shown to increase the number of mucin-containing goblet cells 8 . The utility of rebamipide ophthalmic solution as a therapeutic 9 and a multicenter study 10 . Stable expression of mucin is a novel concept in the treatment of dry eye, and recent studies have shown that its use can be extremely effective 11, 12 . Other studies have shown that rebamipide, in addition to causing an increase in mucin production, also promotes gastric ulcer healing through prostaglandin production in the gastric mucosa 13 , inhibits esophageal and gastric cytokines and chemokines, and has anti-inflammatory effects 14 . Because dry eye is an inflammation of the ocular surface 15 , administration of rebamipide should have an efficacious anti-inflammatory effect for its treatment.
Because dry eye is a disease associated with such problems as eye pain, burning pain, foreign body sensation, and irritation 16 , it greatly reduces quality of life 17, 18 . Recent reports have indicated that quality of life is more reduced in patients who have moderate-to-severe dry eye than in patients who have severe angina or hip fracture or are undergoing dialysis 19, 20 . Thus, a major goal in the treatment of dry eye is to improve symptoms 1 . However, as a review has shown 18 , the signs and symptoms of patients with dry eye often lack correlation. In other words, more than signs must be treated for the proper medical care of patients with dry eye. Therefore, to survey symptoms, clinicians have used a variety of questionnaires, among which the most popular and highly reliable is the Ocular Surface Disease Index (OSDI) 21 . In the present study, we examined rebamipide instillation in patients with dry eye and assessed the improvement of signs and symptoms as evaluated with the OSDI.
Materials and Methods
This study was an open-label, single-arm study that fol- was positive, the ocular surface was considered to be abnormal. Among patients with symptoms, those with abnormal tear dynamics and ocular surface were considered to have definite dry eye, and those with only 1 positive test were considered to have probable dry eye.
Before being enrolled, all patients underwent ocular surface health assessment, including history interview, and completed the OSDI questionnaire ( Table 1) 21 .
The 12 items of the OSDI questionnaire were graded on a scale of 0 to 4. A grade of 0 indicates none of the Subscale scores were computed similarly, with only the questions from each subscale used to generate its own score.
Statistical Analysis
The profiles obtained before and 4 weeks after the administration of rebamipide were analyzed with a paired t-test for the signs and a Wilcoxon signed-rank test for the symptoms. The analysis was performed with the program Statmate III (ATMS Co., Ltd., Tokyo, Japan).
Result
The Japanese Definition and Diagnosis of Dry Eye 2006 criteria indicated that 9 of the 25 patients had definite dry eye and 16 had probable dry eye.
Examination of Dry Eye
From before to 4 weeks after rebamipide was administered the break-up time (Fig. 1a) improved significantly from 2.5±1.56 to 3.02±1.73 (P=0.029), and the FSS (Fig. 1   b) In patients with definite dry eye, the FSS (Fig. 2b) improved significantly (P=0.018) and the LSS (Fig. 2c) showed a tendency to improve (P=0.052). However, the break-up time (Fig. 2a) showed no improvement (P= 0.421). In patients with probable dry eye, significant improvements were observed for both the break-up time (P=0.003) (Fig. 2e) and the FSS (P=0.045) (Fig. 2f) .
In patients who received only rebamipide, improvements were seen in both the break-up time (Fig. 3a) (P= 0.003) and the FSS (Fig. 3b) (P=0.01) . In patients who received both sodium hyaluronate and rebamipide, however, no results showed improvement (Fig. 3e h) .
OSDI Score
From before to 4 weeks after rebamipide administration the OSDI score showed a significant improvement (Fig. 6a) and a nonsignificant change from 40.7±15.9 to 36.6±19.9 (P=0.26) in patients receiving both sodium hyaluronate and rebamipide (Fig.   6b ).
Discussion
The quinolinone derivative rebamipide was developed as a therapeutic agent for gastric ulcer 23, 24 . Its ability to promote the healing of injuries has been demonstrated in a rat model of gastric ulcers 23, 24 . Although rebamipide derives its efficacy by promoting mucin production in the gastric mucosa 4 , it also increases keratoconjunctival mucin expression and the number of conjunctival goblet cells on the ocular surface in rabbits 25 . Mucin is an important wetting agent for the ocular surface and contributes to the tear film stability 26, 27 . The effectiveness of rebamipide, which induces mucin expression, as a therapeutic agent for dry eye has been demonstrated in a large number of patients 10 . In the present study, our overall analysis demonstrated improvements of both break-up time and the FSS. However, a previous study found significant improvements in break-up time, the FSS, and the LSS but no improvement in the Schirmer test 9 . We found similar results in our study when we performed a direct comparison of the individual scores. A stratified analysis showed improvement of only the FSS in patients with definite dry eye but showed improvement of both break-up time and the FSS in patients with probable dry eye. A study that examined patients with Sjögren syndrome found similar improvements in the FSS and the LSS but not in breakup time 28 . While rebamipide is suggested by these data to improve the FSS, its effect on break-up time was unsatisfactory in patients with severe dry eye, such as those with decreased tear amounts. The data of these studies Fig. 6 Changes in the OSDI score in the rebamipide monotherapy group and the rebamipide and hyaluronate combination therapy group a, change in the OSDI score in rebamipide monotherapy group; b, change in the OSDI score in the rebamipide and hyaluronate combination therapy group.
also showed an improvement in the LSS 9,28 which was to a greater than that in our study. A possible reason for this difference is our study excluded patients with Sjögren syndrome. Nonetheless, the LSS in patients with definite dry eye (3.33) was larger than that in patients with probable dry eye (2.44) and showed a tendency to improve (P=0.052). Moreover, these data indicate that the break-up time is more likely to improve in patients with mild dry eye.
Our present study also compared changes in patients who received only rebamipide and patients who received both rebamipide and sodium hyaluronate. Although both break-up time and the FSS improved in patients receiving rebamipide alone, neither improved significantly in patients receiving both rebamipide and sodium hyaluronate. Of the 10 patients who received both rebamipide and sodium hyaluronate, which had been prescribed by a previous physician, 5 had definite dry eye and 5 had probable dry eye. Because patients who received both rebamipide and sodium hyaluronate were not patients with severe dry eye, the above discussion based on the difference in the tear amounts does not apply here. Thus, the cause of the differences in the effect of break-up time and FSS between patients receiving only rebamipide and those receiving both rebamipide and sodium hyaluronate remain unknown. Our present study and the previous report that rebamipide ophthalmic solution improves both signs and symptoms 9 suggest that rebamipide ophthalmic solution is a sensible choice for the treatment of dry eye.
Moreover, because the addition of rebamipide ophthalmic solution provided no improvement in patients for whom sodium hyaluronate alone had been ineffective, rebamipide ophthalmic solution, rather than a combination therapy, probably should be considered for such patients.
We are unaware of any earlier study that has used the OSDI to assess the improvement of symptoms in patients treated with rebamipide. The effects of rebamipide on foreign body sensation, dryness sensation, photophobia, eye pain, and blurred vision have been examined 10 and compared with the effects of artificial tears 29 or 0.1% sodium hyaluronate 9 . However, in these studies the OSDI was not used to evaluate symptoms. These studies 9, 10, 29 showed that rebamipide is efficient for improving symp- Inflammation is deeply involved in the pathology of dry eye. Inflammation reduces tear film stability, resulting in corneal and conjunctival impairments 15 . In fact, increased levels of inflammatory cytokines have been reported in the tear film of patients with dry eye 34, 35 . Rebamipide is a drug of great interest from an antiinflammation viewpoint, because in addition to having an anti-inflammatory affect, it effectively promotes mucin production. These actions have been shown to have inhibitory effects in an experimental model of gastritis 36 , to cause inhibition of inflammatory cell infiltration of gastric mucosa 37 , and to inhibit an inflammatory cytokine 
